Item 8.01 Other Events.
As previously disclosed, on February 3, 2021, GW Pharmaceuticals plc, a public limited company incorporated under the laws of England and
Wales (GW), entered into a transaction agreement with Jazz Pharmaceuticals Public Limited Company, an Irish public limited company (Jazz), and Jazz Pharmaceuticals UK Holdings Limited, a private limited company
incorporated under the laws of England and Wales and a wholly owned subsidiary of Jazz (Bidco), pursuant to which, on the terms and subject to the conditions set forth therein, Bidco will acquire the entire issued share capital of
GW pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (such acquisition, the Transaction).
The completion of the Transaction is conditioned upon the expiration or termination of the waiting period applicable to the consummation of
the Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Waiting Period). The HSR Waiting Period expired on March 22, 2021 at 11:59 p.m. Eastern Time. GW and Jazz continue to expect
to complete the Transaction in the second quarter of 2021, subject to the satisfaction or permitted waiver of the other conditions to closing.
Forward-Looking Statements
This communication contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding GW and Jazz including, but not limited to, statements related to the proposed acquisition of GW and the anticipated timing for the
completion thereof; statements regarding the expectations and beliefs of the board of directors of GW, GW management, the board of directors of Jazz or Jazz management and other statements that are not historical facts. You can generally identify
forward-looking statements by the use of forward-looking terminology such as anticipate, believe, continue, could, estimate, expect, explore, evaluate,
intend, may, might, plan, potential, predict, project, seek, should, or will, or the negative thereof or other variations thereon
or comparable terminology. These forward-looking statements are based on each of the companies current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties, many of which are
beyond GWs or Jazzs control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks
and uncertainties associated with GWs and Jazzs ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including: risks and uncertainties related to securing the necessary regulatory and
shareholder approvals, the sanction of the High Court of Justice of England and Wales and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the
termination of the definitive transaction agreement relating to the acquisition; risks related to diverting the attention of GW and Jazz management from ongoing business operations; failure to realize the expected benefits of the acquisition;
significant transaction costs and/or unknown or inestimable liabilities; the risk of shareholder litigation in connection with the acquisition, including resulting expense or delay; the risk that GWs business will not be integrated
successfully or that such integration may be more difficult, time-consuming or costly than expected; Jazzs ability to obtain the expected financing to consummate the acquisition; risks related to future opportunities and plans for the combined
company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; GWs or the combined companys dependence on the successful
commercialization of Epidiolex or Epidyolex (the trade name for Epidiolex in Europe) and the uncertain market potential of Epidiolex/Epidyolex; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval
process, including the risks that GW or Jazz may be unable to submit anticipated regulatory filings on the timeframe anticipated, or at all, or that GW or the combined company may be unable to obtain regulatory approvals of any product candidates,
including nabiximols and Epidiolex/Epidyolex for additional indications, in a timely manner or at all; disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees,
distributors, suppliers or other third parties; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Jazz ordinary shares, GW American depositary shares or
GW ordinary shares; the possibility that, if Jazz does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Jazz ordinary shares could decline;
regulatory initiatives and changes in tax laws; market volatility; and other risks and uncertainties affecting GW and Jazz, including those described from time to time under the caption Risk Factors and elsewhere in GWs and
Jazzs U.S. Securities and Exchange Commission (the SEC) filings and reports, including GWs Annual Report on Form 10-K for the fiscal year ended December 31, 2020,
Jazzs